Cempra Inc (NASDAQ:CEMP) shares were falling close to 61% after the FDA released briefing documents yesterday for Friday’s AdComm meeting for the biotech …
In a research report released Friday, Cowen analyst Ritu Baral reiterated an Outperform rating on shares of Cytokinetics, Inc. (NASDAQ:CYTK) with a price target of …
Today, Global Blood Therapeutics Inc (NASDAQ:GBT) announced design of the pivotal two-part GBT-440 Phase III HOPE trial in evaluating adults and adolescents with …
Cowen top analyst Ritu Baral shares insight on Sarepta Therapeutics Inc (NASDAQ:SRPT) after speaking with three key opinion leaders (KOLs) regarding the recent approval …
Cowen top analyst Ritu Baral chimes in on Cytokinetics, Inc. (NASDAQ:CYTK) after Amgen, Inc.
Sarepta Therapeutics Inc (NASDAQ:SRPT) just announced two Duchenne muscular dystrophy (DMD) collaborations to evaluate combotherapy with exon skipping. Sarepta will be partering with …
ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) pipeline drug Nuplazid was approved in May to treat Parkinson’s Disease Psychosis (PDP) and launched the following month.
Mast Therapeutics Inc (NYSEMKT:MSTX) must confront how to move forward in the wake of a sickle cell phase III miss for its pipeline …
The biotech world is sounding the alarm on Mast Therapeutics Inc (NYSEMKT:MSTX) and Mirna Therapeutics Inc (NASDAQ:MIRN) after MSTX now has a Phase …
Sarepta Therapeutics Inc (NASDAQ:SRPT) investors have a reason to cheer following the news that the FDA today approved Exondys 51 (eteplirsen), the Company’s lead drug candidate …
